CC BY-NC-ND 4.0 · Journal of Social Health and Diabetes 2019; 7(02): 77-80
DOI: 10.1055/s-0039-1694300
Original Article
Novo Nordisk Education Foundation

Understanding Clinical Inertia in Diabetes

1  Department of Medicine, Government Medical College, Manjeri, Kottayam, Kozhikode, Kerala, India
› Institutsangaben
Funding None.
Weitere Informationen

Publikationsverlauf

Eingereicht: 10. Mai 2019

Angenommen: 18. Mai 2019

Publikationsdatum:
29. Juli 2019 (online)

  

Abstract

Clinical inertia is common in the management of asymptomatic chronic disease such as diabetes, hypertension, and dyslipidemia. In case of diabetes, it exists in all stages of management of diabetes. It can be at population level or at patient level. In addition to assessment of glycemic control with blood glucose and hemoglobin A1C (HbA1C) monitoring, emerging concepts such as “glycemic variability” and “time in range” are increasingly used. Inability to reduce “glycemic variability” and attain “time in range” targets also contributes to clinical inertia.